德国拜耳利伐沙班价格

(Rivaroxaban) is one of the new oral anticoagulant drugs commonly used in clinical practice. A domestic study compared 32 patients each in the rivaroxaban group and the warfarin group. The results showed that the total effective rate of treatment in the rivaroxaban group was 96.88%, which was higher than the warfarin group. The incidence of adverse reactions in the rivaroxaban group was 3.13%, which was lower than the warfarin group. These results indicate that rivaroxaban has similar efficacy to standard treatment, but with fewer major bleeding events and less intracranial bleeding in critical areas than the standard treatment group.

In addition, some researchers included 80 patients with venous thromboembolism in the study. The results showed that rivaroxaban has a significant effect in the treatment of patients with venous thromboembolism (P<0.05). It will not inhibit the patient's coagulation function, nor will it have a major impact on the patient's cardiac function. It is highly safe and worthy of recommendation. So, what is the price of such effective Bayer Rivaroxaban from Germany?

According to Medical Companion Travel, rivaroxaban produced by Bayer in Germany mainly comes in two specifications, one is 20mg*28 tablets/box, and the other is 15mg*28 tablets/box. The prices of both are about $400. Patients in need can either go abroad to purchase, or contact Medical Companion Travel to obtain overseas sales channels. This way, patients can save more money, effort and worry.

Bayer Healthcare’s corporate mission of “technology creates a better life” remains unchanged. In 2008, Bayer Healthcare invested 1.7 billion euros in R&D, accounting for 66% of the Bayer Group's R&D investment. In early 2009, the fourth largest R&D center in the global structure of Bayer Healthcare was established in Beijing. The center has 240 experts and will invest 100 million euros in the next five years. $ for research and development; in 2010, Bayer Healthcare invested 2.06 billion euros in R&D, accounting for 12% of the sales revenue of 16.9 billion euros, and accounting for 68% of the Bayer Group's R&D investment; in 2013, Bayer Healthcare invested 2 billion euros in R&D on its main business. As a drug owned by Bayer, it is worthy of patients' trust.

Recommended hot articles: /newsDetail/86342.html